GSK Pharmaceuticals Valuation

Embed Size (px)

Citation preview

  • 7/26/2019 GSK Pharmaceuticals Valuation

    1/110

    Company's annual report

    Topline growth rate

    COGS %

    SGA%

    R&D expense%

    Working apital re!uirements %

    Capital expen"iture %#$etie tax rate

    Depreiation as a % net lok

    eta

    Det(e!uity ratio

    Risk )ree rate

    #!uity market risk premium

    *ong(term "et

    ook alue o) e!uity

    Cost o) "et

    *ong(term growth rate

    #+,#-TDA

    .(# ratio

    /o o) shares outstan"ing

    #.S

  • 7/26/2019 GSK Pharmaceuticals Valuation

    2/110

    Consoli"ate" inome statement as per ompany reports

    .ART-C0*ARS

    Revenues

    Cost o) reenues

    Gross proft

    Selling1 general & a"ministratie expensesResearh an" "eelopment expenses

    Other 2inome3,expense1 net

    Results rom operating activities

    /et 4nane inome

    Share o) pro4t o) e!uity aounte" inestees1 net o) inome tax

    Proft beore income tax

    -nome tax 2expense3,ene 4t

    Proft or the period

    Average SGA as a % o Sales

    Average COGS as a % o sales

    Average R& expense as a % o sales

    !"#$ margin

    Average !"#$ margin orecasted b !lara Capital

    Average !"#$ margin orecasted b "& Securities

    $a'ing the average o the above our or (C(( pro)ections*

    Average !"#$A margin orecasted b !lara Capital

    Average !"#$A margin orecasted b "& Securities

    $a'ing the average or orecasting or+ard !"#$A margin

    Consolidated +or'ing capital particulars

    PAR$#C,-ARS

    Aounts Reeiale 2A3

    -nentories 23

    Tra"e Aounts .ayale2C3

    .or'ing Capital /A0"1C2

    Other Current Assets 2D3

    Total Current Assets 2A55D3

    Short an" long term loans an"

    orrowings1 urrent portion 2#3

    Other Current *iailities 263

    Total Current *iailities 2C5#563

    /et working apital 2A55D(2C5#563

    3.C as a % o sales

    #$etie tax rate

    Average e4ective tax rate

    iluted !PS /Rs7 per share2

  • 7/26/2019 GSK Pharmaceuticals Valuation

    3/110

    Capex and depreciation calculations /in RS5 6#--#O3S2

    .artiulars

    Gross bloc'

    *ess8Aumulate" "epreiation

    3et bloc'

    Capital expen"itureCapex as a % o) sales

    Average capex as a % o sales

    Depreiation

    epreciation rate

    TotalTotal gloal "eman" )or generi "rugs to inrease at a CAGR o)

    There)ore1 terminal growth assumption

    Growth rate )oreasts

    Growth )oreast as per #lara Capital

    Growth )oreast as per &9 Seurities

    Average gro+th rate

  • 7/26/2019 GSK Pharmaceuticals Valuation

    4/110

    6:; 6:; @ar(=? @ar(=;

    ?1??7< ?1?;7;< ?1==77= =1E>? ;7?E >7E? =7= ?7BE >>7?E >?7?B

    < < < < < ?7? BE;7E ;7B BB=7?E

    ;?7 ;=7? =B

    (B7=> < =7> B7=> 7 7

    (>7 (==7B (=>7== (E7> ==7E >7=>

    ;7>E >B >E=7B7>> >>=

    < < < < < B >E=7B7>> >>=

    (=>77= >BB7? E7; >?7E

    =1=?E7 =1;

    ?=7= ??7= ;>7== ??7= ?

    < < < < < < >7 ;7EE >7>?

  • 7/26/2019 GSK Pharmaceuticals Valuation

    13/110

    ?7=? >E7> >7 ;7EE >7>? E7> >7 ;7EE >7>? E7> >7 ;7EE >7>? ;?

  • 7/26/2019 GSK Pharmaceuticals Valuation

    14/110

    =1=

  • 7/26/2019 GSK Pharmaceuticals Valuation

    15/110

    >>7E>

    >>7E>

    >>7E>

    ==;7>?

    ==;7>?

  • 7/26/2019 GSK Pharmaceuticals Valuation

    16/110

    Dr Re""y's Stok returns

    Date Open .rie Figh .rie *ow .rie Close .rie Returns

    E(Aug(=< =?7> =?>7B> =??;7= =?

    = =?;= =??=7E> (%

    ==(Aug(=< =??< =?= =? =?=>7? (=7;>%

    =;(Aug(=< =?=< =?>> =?7>> =?B>7>> =??; =??>7E> (%=(Aug(=< =?7=> =?> =?;> =?>>7?> =7>%

    =B(Aug(=< =?> =?; =?;7 =??> (=7>? =??< =??7E>

  • 7/26/2019 GSK Pharmaceuticals Valuation

    17/110

    (Ot(=< =>7E> => =>? =>; B> =>B =>>=7 =>B7E> < =>B7E> =>>< =>B7 (E;7;> => =>7> =7;E= ==> =>7 =>B?7;> ((Ot(=< => =B>7B> =>;7 %

    =(Ot(=< =>EE ==7E =>>7= ===7= =7%=E(Ot(=< ==> =? == E =7B7> =

  • 7/26/2019 GSK Pharmaceuticals Valuation

    18/110

    =?(De(=< == =;=7E =B>;7E> ==7;> 7E == =;7E> (De(=< =;< =;E7 =BB> =BE7 (=7E?%

    =(De(=< ==< ==< =B< =B7= ( (=7;>%

    ;;(De(=< =;7 =B=

  • 7/26/2019 GSK Pharmaceuticals Valuation

    19/110

    =(6e(== =>; =>>E =>=?7?> (=7%

    =B(6e(== =>;> =>?7B> =>== =>;B7> ?< =>>< =>;= =>?B7? ? =>7E =EE7 =>?>7 (;B7>> =>< =>= =>>;7; =77;> =>E7;> =>B7> =7>%

    ;(6e(== =>< =>B? =B =>(6e(== =>=B7>> =>7 =>;7B> =7>%

    ;(6e(== =>?? =>>>7B> =>=;7;> =>B7 =7;> =>E< =>;E =>=7=> ;7;> =>E =>> =>BB7> (B => =>E7=> (%

    B(@ar(== =>>> ==E7> =>>> = ;7>B%

    (@ar(== ==?7>> =;> =>EB =7> ( =>;7= ==E7>> ; = =>; =>B7> (EE =E7 =>E7;> >%

    =>(@ar(== =>< =>EB7> =>;7E> =>7> (?7==%

    =(@ar(== =>> => =>> =>B;7> =7B%

    =B(@ar(== =>E =>E =>=>7=> =>;>7> (;7E%

    =(@ar(== =>;7E =>;7E =E; =E7B> (;7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    20/110

    ;(Apr(== =>< =E7E =;B7 = => =>> =7> (; =B7> 7 =;7?> (BE =>EE7; (>7(@ay(== =>EE7= ==7E> =>B?7= =>; (=7E< ==< =>=7> =>7= =>E (E;7B> (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    21/110

    ;(Iun(== =>;< =>7E> =>=7> =>;7=> ;7>>> =>E7> =>;7; =>> =>> =>==7=> =>??7 (=7= =>>> =>=E7= =>;; (?E =>> =>?;7 =>>B7>> ;7?%

    >(Iul(== => =>B7> =>>> =>>7> =%

    (Iul(== =>>E =>> =>== =>;B7E> (;7; =>B< =>= =>>7E ;7%

    (Iul(== =>B7>> =>B< =>?=7>> =>7B> (=7?>%

    ==(Iul(== =>>= =>< =>?=7=> =>?E7> (;B =>>< =>;B =>7 B>7= =>E7> ?7;%

    =(Iul(== =>E =< =>E7>> ((Iul(== =>7=> =>E7> B?7B> (=7;%

    =E(Iul(== =>< = =>B>7=> =>EE7> =7%

    ;>B7; =>B (;7%;=(Iul(== =>B7;> =>>> =>?;7 =>? (=7>?%

    ;;(Iul(== =>>B =>B> =>>? =>E7 =7B%

    ;>(Iul(== =>> =>EB7> =>>?7E> =>7E =7;;%

    ;(Iul(== =>E< =>E; =>> =>BB7 (BE =>E7E =>B =>7E < ==< =>? =EE =>B7 =>B7> (B7> = = => =>EE7; (B =>E7> =>B7? =>B>7 (=7>=%

    (Aug(== =>B7B =>B7B =>;7 =>>7> (=7%

    >(Aug(== =>;> =>?7> =B7=> =>;E7> (=7B7B =E? =>7> =7=;%

    E(Aug(== =B> =>E7 =E;7B (?7E%

    = =>=> =B>7> =7?> (==7E =B>7? =?7= (=< =BE =7> =>7E =E =7=?%

    =B(Aug(== =>=7E =B =>7>> 7>> =EE7E> == =>=7> (?7>E%

    =E(Aug(== =< ==7B =?E>7 =?7= ?7= => =;B =;7> (>7E =? =7; (Aug(== =; => =>7> =>B7; 7> =? =?; =7B> (%

    ;E(Aug(== =>? =EB =>= =7= =7; =E?7> =7E%

  • 7/26/2019 GSK Pharmaceuticals Valuation

    22/110

    ;(Sep(== =>?? =>< =>

  • 7/26/2019 GSK Pharmaceuticals Valuation

    23/110

    E(/o(== ==E =;7E =>E7=> =(/o(== = =>7 =?%

    =(/o(== ==; =; = ==?7 (> (?7E?%

    =(/o(== =>< =>B7> =>< =>>7 > =>7E =>=E7> (;7;>%

    ;;(/o(== =>?= =>7 =>= =>?B7> =7=B%

    ;?(/o(== =>;7 =>>7>> =>?

  • 7/26/2019 GSK Pharmaceuticals Valuation

    24/110

    =;(Ian(=; = =E => =>7> %

    =?(Ian(=; =>7E =?7> =?7 =>>7>> 7 =E7E> =?< ==7 (=7B> =>7= =; =;7 B7?> =7E> (?7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    25/110

    =E(@ar(=; =B< =; => =B>7 (7> =B7E (7;> ?7 =7B =? = ( =7==%

    ;E(@ar(=; =B =E =B%

    ==(Apr(=; =B= =B?E =B=< =B? (;7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    26/110

    ;?(@ay(=; =>; =; => =B>7 =B =7B;%

    ;>(@ay(=; =BB=7?> (%

    =(Iun(=; =>B7E =>BE7E> =>> =>>>7 (=7(Iun(=; =>>> => =>B => =7?%

    =(Iun(=; =>E< =>E =>? =>;7E (;7?%

    =E(Iun(=; =>< =>>> =>; =>?7> E7> ;7E%

    ;=(Iun(=; =>E =>EB7> =>B=7?> =>7;> (E7E> =>B= =>=7 ((Iun(=; => =>E?7> => =>7 EE7>

  • 7/26/2019 GSK Pharmaceuticals Valuation

    27/110

    ;>(Iul(=; =?< =?< =>E> ==7?> ( ;%

    ;B(Iul(=; =;< =?B7>> ==< =;=7= (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    28/110

    ;(Sep(=; =;< =>=7E =;< =B7 =7>%

    =(Ot(=; => => =?E7 =>7?> ( ==7B> ;7;=%

    (Ot(=; =E? =B;7; =E? =B= ;7=%

    >(Ot(=; =B;E7E> =B?;7 =< =E?7? (=7%

    (Ot(=; =B =B=7>> =; =EB7E> =E>7;> =B7>> %= ((Ot(=; =E< =B

  • 7/26/2019 GSK Pharmaceuticals Valuation

    29/110

    (De(=; =?B7>> =>< ==7=> =B7> %

    B(De(=; =7> =7> =?< =?7?> ( ;7>=%

    ==(De(=; =E? =E=;7E => ==7 (< =;7B =;7>> =??7B (E =? =?E7>> (?7?> %

    ;7 (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    30/110

    (6e(=? => =E7 = =>7> (=7EE%

    ==(6e(=? = =E

  • 7/26/2019 GSK Pharmaceuticals Valuation

    31/110

    =(Apr(=? =>> =E?;7E =>> =E=E7>> ?7>%

    =B(Apr(=? =E=7 =E??7 =B =E (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    32/110

    ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    33/110

    ;(Aug(=? ;=; ;=7; ;=;> ;=>B%

    ;B(Aug(=? ;=> ;=E7?> ;== ;=;7;> ?%

    ;(Aug(=? ;=>< ;=E< ;=?>7 ;=B;7?> %

    ?7E> ;;=; ;;E?7;> =7E;%

    ;(Sep(=? ;;B; ;?=< ;; ;;BB7E ( ;;=< (;7E%(Sep(=? ;;?< ;;E7E> ;;=< ;;BE7 ?7=%

    >(Sep(=? ;;> ;??? ;;B ;;E?7; E%

    (Sep(=? ;;E< ;?> ;;B ;;?7E ( (7>> ;;7B> ( ;;7 ;== ;;;7 (< ;;B; ;;?=7 ;;7 (=7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    34/110

    ?=(Ot(=? ;>;> ;>> ;?> ;>>7E> (;7%

    =(/o(=? ;> ;E7? ;< ;B 7= ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    35/110

    (Ian(= ;EB ;> ;< ;B;7 (=7=?=7E> =7;%

    E(Ian(= ;>< ;>E7E> ;>?= ;>B7E> ;7;=%

    =E ;;E7E> ;>> ;;>7> =7>%

    =?(Ian(= ;;>7> ;?> ; (Ian(= ; ;;7E ;;7 ;> (>7E> ;< ;?>7; ;>7;> ( ;>;7 ( ;?=7> ;E7>> >%;E(Ian(= ;< ;> ;>7> ;>>7? ;=E7;> (=7?%

    ?=(Ian(= ;; ;? ;E7 (;7(6e(= ;>E ;=;7E> ;>< ;>E7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    36/110

    ==(@ar(= ;E= ;B;7 ;7?> ;B7> ( ;B=> ;B> ;EE7E> ;E= ;B?7=> =7?%

    =(@ar(= ;B; ;BE< ;B=? ;BB>7E =7>?%

    =(@ar(= ;B> ;=> ;BBB7> ;BE;7= %

    =E(@ar(= ;BEE ;?>7;> ;BB ; ;BB7 ( (@ar(= ;B>< ;B< ;B=? ;B;=7?> (=7 ;B?E7 ;;7> ;?7 (?7=?%

    ;B(@ar(= ;B ;B ;>B ;>B7= (=7%

    ;(@ar(= ;%

    =(Apr(= ;>< ;=; ;>B? ; ;?7E (%

    B(Apr(= ;B ;< ;>E ;E7> ;?;7 ;>> ;; ;>E7= (;7B;%

    ==(Apr(= ;>>< ;>E ;>;; ;>BB< ;B< ;>BB7> E< ;>E ;>??E7?> (=7%

    =B(Apr(= ;>< ;>B ;>;7B> ;>> >;7; ;>BB ;>< ;>>;7> (B7E ;>B7E ;>7= ;>>;7B (< ;>>7B ;>>< ;>>7> (Apr(= ;> ;?7E> ;> ;;>7E> ;7?%

    ;(Apr(= ;;E ;B ;;E ;B;7?> =7BB%

    ;E(Apr(= ;B ;E< ;;7?> ;7>> (? ;B7 ;B?B7> =7=E%

    >(@ay(= ;B< ;B>< ;B;> ;B;E7E (< ;B;7> ;B7B> %

    B(@ay(= ;B?B7= ;B>; ;B;E7> ;B?B7?> ( ( ;B?7 ;B ;B=E7=>

  • 7/26/2019 GSK Pharmaceuticals Valuation

    37/110

    ; ( ;??%;E(@ay(= ;?B7E> ;?EE ;?=7;> ;?BB7B =7?;%

    ?> ;B; ; ;?7> ;???7 ;?? (?7=>%

    (Iun(= ;??> ;?> ;?=?7 ;?;>7; (>%

    >(Iun(= ;?E ;?E ;;E? ;? ;?=7E ;?E7;> =7BE%

    E(Iun(= ;?>7> ;?= ;?< ;?>=7>> 7> ;?E; =7B;%

    ==(Iun(= ;; ;?>7> ;?EB7; ;?=7E> =7B%=;(Iun(= ;?;7 ;?7 ;;< ;? ;; ;7? =%

    =(Iun(= ;?> ;;7;> ;7;> ;;?7= (%

    =B(Iun(= ;?< ;?< ;? ; =7%

    ; ;?E7?> (< ;>7 ;?= ;7= 7 ; 7=> ; ;>?7B ;BE7?> %

    ;(Iun(= ;? ;>; ;; ;>

  • 7/26/2019 GSK Pharmaceuticals Valuation

    38/110

    ;;(Iul(= ;7 ;B?>7E ;;7 ;B=E7;> ;7?B%

    ;?(Iul(= ;B;7;> ;BB7; ;B=;7= ;B??7E> %

    ;(Iul(= ;B? ;B>7; ;E=7E ;B=> ((Iul(= ;B7= ;B>7> =7?7> ;B7=> ;B;?7> ;B7B ;77 ;BB7> ; ;B>7 (=7;%

    (Aug(= ;BB> ;B< ;B>=7>> ;B7?> (Aug(= ;BBB ;7> ;BBB7> ;B>>7E> E7;> ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    39/110

    ;(Sep(= ?? ?; ?;;B7;> (;7=%

    ;E(Sep(= ?;;> ?;B7 ?=EB7 ?; ( ?;=7; ?;;B7> (7?B%

    E(Ot(= ;EE> ? ;E>=7=> ;EE<

  • 7/26/2019 GSK Pharmaceuticals Valuation

    40/110

    E(De(= ??;E7 ??BE7; ??;; ??>7> =7;=%

    = ?7=> (%

    =(De(= ??=> ??? ?=;; ?=;7 (7?;%

    =B(De(= ?==B ?;=;7 ? ( ?;;= ?=B= ?=E7> =7>?%

    ;;(De(= ?=EE ?;>; ?=B ?;7 =7E%

    ;?(De(= ?;?> ?;?>7E> ?=E7B ?;7;> (=7;B%

    ;(De(= ?=< ?=E (;7> ?==>7= ?=;E7> ( ?=> =7;%

    ?=(De(= ?=E7 ?;< ?=E7 ?;7E> ;7 ?; ?; ?;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    41/110

    =;(6e(=> ?=; ?? ?=; ??;B7> >7E%

    =?(6e(=> ??B< ??B< ??;; ???>7E> %

    =(6e(=> ?? ??EE7E ???B7;> ??> ???E ??B7 ??=>7 ??>7B ???7 ??E7 ??;;7> ???7 7; ?;B7E> (;7%

    ;(6e(=> ?;>=7= ?;B7> ?;;B7> ?;7= ( ?;>< ?;E ?; ?;B7B ?;;7? ??E7E> ?;; ??E7> ;7;E%

    ;(@ar(=> ??>; ?=7B ???;7 ?? =7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    42/110

    ;;(Apr(=> ?B ?>; ?B ?>>7 ;7EB%

    ;?(Apr(=> ?>B< ?>BB7 ?>==7; ?>;7? (=7=%

    ;(Apr(=> ?>? ?>E7E ?B=7? ?>7> (=7 ?E ?>= ??>7 ?? (?7 ??BE ?;E7B> ???E ?=;7> ?;7B> ?E7> ??> (=7 ? ??E< ? ?;E< ??>>7;> (=7 ??< ??B7; ?;> ?;=7B> (;7=E%

    (@ay(=> ??;>7> ??7 ??=;7> ??E7? ;7 ??>> ? ?? ?E;7> ??=7 ?>7 ?7 ?>7 ?>;E ?> ?E;7E ?>?7E ?B ?>=< (@ay(=> ?>=7B ?>=7B ?B< ?E=7 (;%=(@ay(=> ?> ?7%

    =E(@ay(=> ?=? ?E ?>=7;> ??B7> ?>E=7? ?; ?=> ?>7B> ?>E7?> ??E7 =%

    ;>(@ay(=> ?>7E> ?;7 ?>BB7? ?>7E> (=7E%

    ;(@ay(=> ?>E7> ? ?>< ?>7>> (=7 ?>=7> ?>EB ?>>7>> =7= ?=>7> ?=>7> ?>;?7= (=7B%

    ;E(@ay(=> ?>?;7>> ?>B? ?E;7> ?>?;7B> ?>== ?>B;7= ?>=< ?>?E7 ?>?> ?>?> ?=7 ?B7> (=7%

    ?(Iun(=> ?> ?;7 (=7?%

    (Iun(=> ?>> ?E ??EE7=> ?;=7E ( ??> ?B ?B ? ???>7E ?? ??E ??E ?? (=7?;%

    =;(Iun(=> ??;> ???E ?? ??=B7;> ??= ??? ??= ??;7> ?? ?? ??< ??EE ??> ??B7? =7 ?=< ?;?7 ??B< ??BE7> %

    ;;(Iun(=> ?=>7> ?;B ? ?;?7 =7? ?=> ?> ?=> ??>7;> ??> ?B? ?=>7 ???7> (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    43/110

    ;>(Iun(=> ???7> ?> ?7 =7>>%

    ;(Iun(=> ?E7? ?>?E ?E7? ?>;;7? =7 ?>< ?;7> ?>;B7= ?BB7> ?>>> ?>?> ?7E> ?>?> ?>B7B ?>> ?>> ?>;>7 ?>B7; (B%

    ?(Iul(=> ?> ?>EB ?> ?>=7? ?>>7> ?B= ?> ?B==7B> ?7%

    B(Iul(=> ?B==7B> ?B> ?B;> ?BB7> ?B

  • 7/26/2019 GSK Pharmaceuticals Valuation

    44/110

    @arket returns

    Date Open Figh *ow Close

    E(Aug(=< ===7== =? ==?E7E =;B7>

    =

  • 7/26/2019 GSK Pharmaceuticals Valuation

    45/110

    (Ot(=< ; ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    46/110

    =?(De(=< =E(De(=< =EBE=7;; =E=B7= =E>B=7? =EB7BB

    =(De(=< =EE7> =EEB7;; =E>>7?> =E7>

    ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    47/110

    =(6e(== =;B?77 =;=7=; =??;7= =;??7BE =>7;

    ;=(6e(== =;?7> =>B7E =7=; =B>>E7B =B?;7=;>(6e(== =BBB>7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    48/110

    ;(Apr(== =E>E7?; =E;7=? =E?>7?>

    ;B(Apr(== =E=?;7> =E>;7 =E;>7E; =E;E;7B =E?>7> =E7 =E=?>7E

    ;(@ay(== =E;;7 =E;>?7B =E>7B =EE7?7E

    (@ay(== =>>7?? =? =E7?>(@ay(== =7B= =>E7;= == =;=

    (@ay(== =;E7B =>7 =;B=7 =>=7=

    E(@ay(== =;7? =?7> =?B7;= =>;7E

    =7E> =E7?B =;E7=;7BB

    ==(@ay(== =>B;7= =;;7 =>7E? =>7E

    =;(@ay(== =>;>7?; == =B;7> =;?=7;

    =(@ay(== =E;7 =E;7 =?=E7 =?>7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    49/110

    ;(Iun(== =E?7>E =>;B7> =?;?7 =E;7>

    ;E(Iun(== =>>;7=E =B=>7?E =>>;7=E =E?7

    ?7B

    =(Iul(== =EB7E =E

  • 7/26/2019 GSK Pharmaceuticals Valuation

    50/110

    ;(Sep(== =E?7B =EE7 =7(Sep(== =B7? =BB7;= =E;;7?= =B

    (Sep(== =B==7

    E(Sep(== =B=E7B> =B;==7 =? =7EB

    =;(Sep(== =7;> =7;> =?E?7;;7B= =B>7;; =?B7? =B(Sep(== =?B7B =E;;7 =>>7B =B7>

    =(Sep(== =B =E7> =E??7?

    =E(Sep(== =>7E? =>7E? =B7?>

    ;7 =B>7E =B

  • 7/26/2019 GSK Pharmaceuticals Valuation

    51/110

    E(/o(== =B=7E =B>7? =B??=7;? =B?;7=

    ==(/o(== =B=B7E =B;BE7;? =B; =B?E=7EE =B(/o(== =B =BB>7B

    =B(/o(== =B>7 = = ==7B=

    =(/o(== =?B7B =?E7E ==7EE =?B=7>=;=(/o(== =;EB7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    52/110

    =;(Ian(=; ===B7=E ==B7> =>E;7>E =

  • 7/26/2019 GSK Pharmaceuticals Valuation

    53/110

    =E(@ar(=; =B>?=7B =B>=7 =B;;7? =B;B?7?B

    ;E =B?BB7>E =B =B;7B

    ;B(@ar(=; =B;7; =B

  • 7/26/2019 GSK Pharmaceuticals Valuation

    54/110

    ;?(@ay(=; =>EE>7= =

  • 7/26/2019 GSK Pharmaceuticals Valuation

    55/110

    ;>(Iul(=; =EE7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    56/110

    ;(Sep(=; =B= =B;7B

    =(Ot(=; =B7 =?7> =B>7; =;?7E=

    ?(Ot(=; ==7E =E7; ==7>B =E7E

    (Ot(=; =E?E7B> =E=

    >(Ot(=; =E==>7E =E=?B7;E =B>B7? =E?7

    (Ot(=; =EE7=E =EE7=E =7 =B =>7 =B;;7 =BE?7?= =?7? =B>7=

    =>(Ot(=; =EE7> =B=?7>>

    =(Ot(=; =B7B> =E7; =>BB7B

    =B(Ot(=; =B7B; =B7=E =>?>7?B ==?7 = =>B7= =BE=7E?

    =E(Ot(=; =B =BE7>E ===7B =;7?=

    ;;(Ot(=; =>>7E? =

  • 7/26/2019 GSK Pharmaceuticals Valuation

    57/110

    (De(=; =EB>7;?7;> =E=7; =E7

    B(De(=; =E>=7 =E>=7B =E??7=? =E;7=

    =>7;

    =?(De(=; =E

  • 7/26/2019 GSK Pharmaceuticals Valuation

    58/110

    (6e(=? =E>BB7=E =E7=B7>E =E>?7 =E=7E =EB

    =;(6e(=? =EE7B =E>?7>? =E?7>? =E>=7

    =(6e(=? =EE7;> =E>>7 =E;7E; =E>B7;= =E?>7B;

    ;

    ;=(6e(=? =E>E7 =E>>7> =E;E7B =E?;>7?

    ;;(6e(=? =E?=7E =E =E;E7? =E?=B7(6e(=? =E?>7?? =E==7= =E;?B7E =E??=7E

    ;(6e(=? =E;E; =E;=;7E; =E=?7>

    (@ar(=? =EB7B =EB

  • 7/26/2019 GSK Pharmaceuticals Valuation

    59/110

    =(Apr(=? =?>7?; =BB=7?? =?;>7B? =B7E?

    =B(Apr(=? =BB?7> =E7 =B?7 =B?=7=

    =(Apr(=? =E>7? =E7 =E=7= =E7BB

    ?(@ay(=? =EB =EB7> =E>;7? =E>B>7

    (@ay(=? =E>B=7 =EE7;E =E>>7?= =EB?7

    B(@ay(=? =EEB7?? =EE=B7 =EEB7?? =E7E>

    (@ay(=? =EE>

  • 7/26/2019 GSK Pharmaceuticals Valuation

    60/110

    ;>;7=;

    ;B(Iun(=? =B=7== =E;>7B> =7; =B>7E>

    ;(Iun(=? =E;7 =E>E7? =E?B7>B =E>BB7?E

    ;(Iul(=? =E>B?7E? =E>E7= =E;7B> =E?7;

    ?(Iul(=? =E?B7== =E?B7== =E=B7?= =E=BB7B

    (Iul(=? =E;>7=; =E>777BE =E7;

    (Iul(=? =E=7E =E;;7E =E=>7E; =E?;7BB

    E(Iul(=? =E?EE7?B =E =E? =E?E7

    =7E? =E;?B7E= =E;E7=;

    ==(Iul(=? =E7 =EB;?7>= =E7 =EB77>E =EE>7B=>(Iul(=? =EE;7= ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    61/110

    ;(Aug(=? = =B;7=E =7E? =>>7=?

    ;B(Aug(=? =

  • 7/26/2019 GSK Pharmaceuticals Valuation

    62/110

    ?=(Ot(=? ;=7> ;=7B= ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    63/110

    (Ian(= ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    64/110

    ==(@ar(= ;=E=7? ;;; ;=BB;7== ;=;7;

    =;(@ar(= ;=BE?7?; ;=E>7E> ;=B7= ;=>7;;

    =?(@ar(= ;=B?7= ;=EE=7? ;=B;?7?; ;=>B?7 ;= ;;7? ;=B;7 ;=B;7 ;=BB7E; ;=B;>7>; ;=B>>7?;

    ;(@ar(= ;=;B7> ;; ;;>7

    ;>(@ar(= ;=E7?= ;;7;=

    ;(@ar(= ;;=?7B= ;;=B;7; ;;>7;? ;;>7BB ;;;E>7> ;;7

    ;(Apr(= ;;>> ;;>E;7= ;;B?7 ;;>>=7E?(Apr(= ;;>E7=E ;;; ;;?E7; ;;>;>7;= ;;??E7 ;;?>E7>

    B(Apr(= ;;?>>7> ;;=7; ;;=EB7>= ;;??7>

    E(Apr(= ;;?E7;= ;;B(Apr(= ;;E7??7= ;;;B7?E ;;;BB7;?

    =B(Apr(= ;;?;B7B ;;7E ;;?=;7=E ;;;7

    ;=(Apr(= ;;7B> ;;BE>7> ;;?7B> ;;B7?

    ;;(Apr(= ;;BB=7; ;;>?7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    65/110

    ;>>7?= ;>B7= ;;EE7>? ;?B7

    ;=(@ay(= ; ;=>7B ;;E77; ;>;7B ;?;7 ;?B7

    ;?(@ay(= ;>?>7= ;B>7 ;B

    ;(@ay(= ;E=?7E ;>=B>7;; ;??7E ;B=7

    ;B(@ay(= ;B7= ;BBB7?= ;;;7?? ;>E7>=

    ;(@ay(= ;>E=7= ;?7?? ;7= ;>>7;?7=? ;>;7; ;; ;;?7=>

    ?

  • 7/26/2019 GSK Pharmaceuticals Valuation

    66/110

    ;;(Iul(= ;>B7 ;B>E7=? ;>?=7 ;>B>7; ;>>?=7? ;>B;?7=

    >(Aug(= ;>=B7 ;>E;7?; ;>>;7? ;>E> ;>E;=7> ;>>7;B

    B(Aug(= ;>7B= ;>BB7 ;>>;7 ;>>E7;?;7; ;>?;E7=

    ==(Aug(= ;>B7B ;>>>?7 ;>?B7 ;>>=E7;

    =;(Aug(= ;>B

  • 7/26/2019 GSK Pharmaceuticals Valuation

    67/110

    ;(Sep(= ;;E7? ;B;=7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    68/110

    E(De(= ;=?7;; ;=>B7>? ;BB?7; ;BBEB7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    69/110

    =;(6e(=> ;> ;?7>; ; ;7=

    =?(6e(=> ;7EE ;E=>7B ;?>7B ;E ;E=B7?> ;E7

    =(6e(=> ;E=?7;;7 ;E= ;E;7;B

    ; ;E7;= ;E;7 ;E?=7> ;E?;7E ;E=?7= ;EB>7==;(6e(=> ;E> ;E=?7E ;E ;E==>7?; ;E;E7? ;EB7= ;E ;>7=; ;E;>7??7; ;E>B7?; ;E;>E7BB ;E>E7=

    ?(@ar(=> ;E> ;EE?B7;B ?=7?; ;E=;7B ;E7E>

    E(@ar(=> ;E?=7> ;E?;=77B> ;?7;? ;E7=B

    =;(@ar(=> ;BE7= ;EB=7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    70/110

    ;;(Apr(=> ;BB>7 ;BEB7; ;B?>7 ;BE ;BEBB7;B ;7 ;B ;B;E7== ;B?7B ;B?B7E

    ;B(Apr(=> ;B>>7E ;B>B7; ;B==7>> ;B=B7EE

    ;(Apr(=> ;B;=>7= ;B;7= ;B ;B?E7?

    ;E(Apr(=> ;B?E>7B= ;B?7E ;B=B7> ;B;;>7E?

    ? ;B;;7 ;B;;7 ;EB7> ;B ;B;?B7> ;B=>E7> ;BEE

    >(@ay(=> ;B>=7?; ;B

  • 7/26/2019 GSK Pharmaceuticals Valuation

    71/110

    ;>(Iun(=> ;B ;B?>7B ;BE>7EB

    ;(Iun(=> ;B7= ;B==7

    ;E(Iun(=> ;B>=77?; ;B;7=>

    ? ;B;B7?E ;B=7>? ;B>B ;BB ;B;?7> ; ;BBEE7E= ; ;BEB?7=; ;=?>7? ;BEB7> ; ;B>B7; ;;?>7?= ;BBB7 ;; ;;;7;? ; ;7B; ;BB7B;

    E(Iul(=> ;B=7E ;BBE7=? ;B>B?7

    = ;BB7? ;BB;E7 ;B>? ;BB?E7?; ;7 ;BE7E; ;E ;B>?7E ;BE?;7E

    =>(Iul(=> ; ;;>E7B ;B7? ;;>7= ;7=;

    =B(Iul(=> ;B7?; ;=B7 ;?7?=; ;>7; ;>E7=? ;?=E7? ;; ;?=7; ;>=7 ;=>E7; ;>7; ;B7?? ;?=>7?B ;?B ;?E ; ;==B7> ;B>;E7>B ;B>=7?

    ;(Iul(=> ;B? ;B=7?E ;B>E7;?

    ;E(Iul(=> ;B>

    ?=(Iul(=> ;B=7>= ;==7=B ;B=7>= ;==7>

    ?(Aug(=> ;7 ;;;?7 ;;E=7 ;?>E7E ;=?7E ;;E7=?

    B(Aug(=> ;?;B7== ;??>7B ;=E?7E? ;;?7?E

  • 7/26/2019 GSK Pharmaceuticals Valuation

    72/110

    Returns eta alulations8

    Coariane 2stok returns1 market returns3 >7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    73/110

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    74/110

    %

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    75/110

    %

    =7=?%

    (=7%

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    76/110

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    77/110

  • 7/26/2019 GSK Pharmaceuticals Valuation

    78/110

  • 7/26/2019 GSK Pharmaceuticals Valuation

    79/110

    (=7=%

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    80/110

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    81/110

    (=7=%

    (;7?

  • 7/26/2019 GSK Pharmaceuticals Valuation

    82/110

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    83/110

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    84/110

  • 7/26/2019 GSK Pharmaceuticals Valuation

    85/110

  • 7/26/2019 GSK Pharmaceuticals Valuation

    86/110

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    87/110

    ;7==%

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    88/110

    (;7B%

  • 7/26/2019 GSK Pharmaceuticals Valuation

    89/110

    %=7?%

    ;7;;%

    =7>?%

    ?7BB%

  • 7/26/2019 GSK Pharmaceuticals Valuation

    90/110

  • 7/26/2019 GSK Pharmaceuticals Valuation

    91/110

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    92/110

    (

  • 7/26/2019 GSK Pharmaceuticals Valuation

    93/110

  • 7/26/2019 GSK Pharmaceuticals Valuation

    94/110

    =7;=%

  • 7/26/2019 GSK Pharmaceuticals Valuation

    95/110

  • 7/26/2019 GSK Pharmaceuticals Valuation

    96/110

    (=7=>%

  • 7/26/2019 GSK Pharmaceuticals Valuation

    97/110

    %

    =7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    98/110

  • 7/26/2019 GSK Pharmaceuticals Valuation

    99/110

  • 7/26/2019 GSK Pharmaceuticals Valuation

    100/110

    < =

    6:; 6:;

    BoB gro+th rate orecasts 17;5;;%

    3et Sales 7=:D7:< 788D8?;

    #-T ?BE ?=;B

    3OPA$ 99?

  • 7/26/2019 GSK Pharmaceuticals Valuation

    101/110

    ; ?

    6:;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    102/110

    Cost o) apital estimation

    -nterest on long(term "et 2as per ompany reports32in -/R millions3

    Outstan"ing long term "et as o) @arh ;2-/R millions38

    .retax ost o) "et8

    Total sharehol"ers' )un"s as o) @arh ;

    Weight o) "etWeight o) e!uity

    =< year G(se with time to maturity as o) ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    103/110

    7B

    ?=7;

    =>7

  • 7/26/2019 GSK Pharmaceuticals Valuation

    104/110

  • 7/26/2019 GSK Pharmaceuticals Valuation

    105/110

    Growth )oreast o) #arnings per share8

    Dilute" #.S 2as per ompany reports3

    :o: growth

    was"

    6orwar" 4nanials )or 6:=#Dilute" #.S 26:=#3

    /et Sales 26:=#3 2in -/R million3

    Outstan"ing "et 26:=#3 2-/R millions3

    Sales per shares

    #-TDA 26:=#32-/R @illions3

    Aerage )orwar" @ultiples in -n"ian .harma in"ustry as per "ata otaine" )rom loo

    #+,Sales

    #+ o) 4rm

    +alue o) e!uity+alue per share as per #+,sales multiple

    #+,#-TDA

    #+ o) 4rm

    +alue o) e!uity

    +alue per share as per #+,#-TDA multiple

    .,#

    #stimate" prie per share as per .,# multiple

    .,Sales per share

    #stimate" prie per share as per .,Sales multiple

  • 7/26/2019 GSK Pharmaceuticals Valuation

    106/110

    ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    107/110

    3ame !st PI! Current Br Current 6ar'et Cap

    Aerage ?=7BB >

  • 7/26/2019 GSK Pharmaceuticals Valuation

    108/110

    PI! Ratio /$$62 PI! Ratio (B 9 !EI!"#$A /$$62 !EI!"#$A /(B72

    ;7= ;;7E ;?7> =7>

    ?=77?>

    ?>7?= ;;7=; ;7 =E7B=7B> ;=7== ;7= ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    109/110

    !EISales /$$62 !EISales /(B72 PISales Ratio /$$62 PISales Ratio /(B72

    7=> >7= >7B; >7?

    7E 7= 7 7??

    7; >7B 7? >7

    >7?; 7 >7;? 7=;

    ?7 ?7B ?7==

    >77?= 7 7B /7A7

    7; 7= 7; ?7E=

    ?7> ?7;? ?7; /7A7

    7B ;7; 7 ;7>

    /7A7 /7A7 /7A7 /7A7

    B7; B7;> 7= 7>

    ;7= ;7E ;7B= /7A7

    ;

  • 7/26/2019 GSK Pharmaceuticals Valuation

    110/110

    PISales Ratio /(B92 P!G Ratio PI(C( PI"oo' !EIShr

    ?7>E =7B> E=7 7> ;>>>7=

    ?7 =7> B>7;; B7? /7A7

    ?7E= =7?E =7> E77> /7A7

    ;7 =7=? =7BB =7E >B7 B7B ?B=7>

    =